Events

GeneCentric Announces “Advances in RNA-based Biomarker Development for Precision Oncology” Webinar Series

This three-part webinar series, “Advances in RNA-based Biomarker Development for Precision Oncology”, will highlight trends in RNA-based biomarker development for precision oncology, ranging from the use of gene expression signatures in the development cancer therapies, to the development of RNA-based companion diagnostics, to novel applications for RNA-based biomarkers in cancer treatment. Part 1 is August 24th, with Parts 2 and 3 September 10th and October 8th.

GeneCentric has moved its offices

GeneCentric Therapeutics is now located at 100 Capitola Dr, Suite275 Durham, NC 27713

Covid-19 Status

GeneCentric Therapeutics continues to monitor the evolving novel Coronavirus (COVID-19) situation closely. We are following the Centers for Disease Control and Prevention (CDC) recommendations on prevention and spread of the virus along with specific guidance for travelers. Currently, the company doesn’t anticipate any changes with its current client projects and will continuously update clients.

Dr. Myla Lai-Goldman discusses GeneCentric’s Cancer Subtyping Platform (CSP™) with Healtheo360’s David Duplay and Courtland Long

Dr. Myla Lai-Goldman discusses GeneCentric’s Cancer Subtyping Platform (CSP™) with Healtheo360’s David Duplay and Courtland Long

GeneCentric to Present at the Personalized Medicine World Conference

On January 26, 2016 at 2:00 pm, GeneCentric’s Hawazin Faruki will speak at the Personalized Medicine World Conference (PMWC) 2016 Silicon Valley on “Genomic Tumor Profiling – Advancing Beyond Gene Mutations.” PMWC 2016 SV, co-hosted with Stanford Health Care and UCSF on January 24-27, will gather 1200 multidisciplinary attendees and key stakeholders from the business, […]

GeneCentric Selected to Participate in the Southeast Venture Philanthropy Summit

On May 5, 2015, GeneCentric will present at the Southeast Investor & Venture Philanthropy Oncology Summit 2015. The Summit features more than 30 of the Southeast’s top private oncology companies. Attendees come from small and large oncology-focused companies, venture philanthropies and investment groups.

GeneCentric is 1 of 13 Companies Selected to Participate at this year’s CED Life Science Conference Showcase

GeneCentric is one of only 13 companies selected to participate at this year’s CED Life Science Conference Showcase. Dr. Myla Lai-Goldman, CEO of GeneCentric, will be presenting an overview of the company’s science and business model. The presentation will take place on Tuesday, March 3rd at 4:10pm at the Convention Center in Raleigh, North Carolina.

GeneCentic Presents Validation Study of it’s Lung Cancer Gene Expression Subtyping Panel

On November 15, 2014, at the annual Association of Molecular Pathology meeting in Maryland just outside Washington DC, GeneCentric presented a validation study of its Lung Cancer Gene Expression Subtyping Panel (LSP) using RT-qPCR of formalin fixed paraffin embedded samples. The LSP gene signature has been shown to be a robust method for classifying lung […]